Headache . 2025 Dec 19. doi: 10.1111/head.70000. Online ahead of print. Benoit Gerard , Hubert Praudel , Michel Lanteri-Minet , Elise Van Obberghen , Fanny Rocher-Moreau , Johanna Rousset , Ulysse Jacquier , Sylvie Leroy , Margot Delin Abstract Background: Eptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody used for
Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans
Neurology and therapy 2025 Dec 18. doi: 10.1007/s40120-025-00874-z. Online ahead of print. Peter J Goadsby , Alexandra J Sinclair , Shazia K Afridi , Christian Lucas , Jerôme Mawet , Michel Lanteri-Minet , Xavier Moisset , Hans Christoph Diener , Charly Gaul , Tim Patrick Jürgens , Marja-Liisa Sumelahti , Margarita Sanchez
Migraine-related disability according to headache frequency subclassifications: A systematic review and meta-analysis
Cephalalgia 2025 Oct;45(10):3331024251385965. doi: 10.1177/03331024251385965. Epub 2025 Oct 17. Manjit Singh Matharu , Stephen Silberstein , Hsiangkuo Yuan , Deborah Edgar 3 Roos Colman , Todd J Schwedt , Michel Lanteri-Minet , Mark Obermann Abstract BackgroundThis systematic review and meta-analysis synthesized migraine-related disability outcomes according to headache frequency subclassifications,
Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study
European Journal of Neurology 2025 Aug;32(8):e70328. doi: 10.1111/ene.70328. Stewart J Tepper, David W Dodick, Michel Lanteri-Minet , David Dolezil, Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D Mikol, Mahan Chehrenama, Denise E Chou, Zilu Liu, Gabriel Paiva da Silva Lima Abstract Background: Erenumab-induced medication overuse headache (MOH) remission in participants with
Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study
The Journal of Headache and Pain 2025 Jul 2;26(1):153. doi: 10.1186/s10194-025-02086-0. M Lanteri-Minet , C Casarotto, O Bretin, C Collin, M Gugenheim, V Raclot, A Cases, P A Squara, W Aissani, A Saighi, H Lefebvre Abstract Background: The most used treatments for migraine attacks are triptans, yet a considerable proportion of
Validation of an 8-item self-administered questionnaire for assessing migraine-related sensory hypersensitivities (MHQ-8)
The Journal of Headache and Pain 2025 May 26;26(1):128. doi: 10.1186/s10194-025-02067-3. François Gabrielli , Melissa Zuel , Camille Magaud , Sophia Sickout-Arondo , Bruno Pereira , Jérémie Dassa , Solène De Gaalon , Geneviève Demarquay , Anne Donnet , Anne Ducros , Pierric Giraud , Evelyne Guégan-Massardier , Christian Lucas , Jérôme Mawet